Trametinib + dabrafenib B-Raf enzyme inhibitors  

     

Select             pdf
Trial Studied trt Control trt patientstagsROB Trial resultdeath (overall survival) progression or death (progression free survival PFS)

melanoma  

Flaherty, 2012      NCTtrametinib and dabrafenibdabrafenibsuggesting-61%
COMBI-D (Long), 2014        NCTtrametinib and dabrafenibdabrafenib1L unresectablesuggesting-37%-25%
COMBI-AD, 2017      NCTtrametinib and dabrafenibplaceboadjuvantLow risk of bias suggesting-43%-53%
COMBI neo, 2018      NCTtrametinib and dabrafenib SOCadjuvant -
COMBI-V (Robert), 2015      NCTtrametinib and dabrafenibvemurafenib1Lsuggesting-31%-44%